Tim Meyer
MBBS, PhD
Professor of Experimental Cancer Medicine
👥Biography 个人简介
Tim Meyer is a hepatobiliary oncologist who participated in pivotal trials of pembrolizumab-based regimens in advanced HCC including KEYNOTE-240 and KEYNOTE-524 (lenvatinib plus pembrolizumab). His translational research examines immune biomarkers in HCC including the tumor immune microenvironment and circulating correlates of response. He leads UK multi-center clinical trials in hepatocellular carcinoma and biliary tract cancers, including Novel Agent trials in the NIHR Clinical Research Network. He is a key contributor to ESMO hepatobiliary cancer guidelines.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Tim Meyer 的研究动态
Follow Tim Meyer's research updates
留下邮箱，当我们发布与 Tim Meyer（University College London Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment